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 Renal cancer causes over 100,000 annual deaths worldwide, and the 
incidence is increasing. Clear cell renal cell carcinomas (CCRCC), 
constituting 75% of renal cancer, are known for their high metastatic 
frequency and resistance to conventional therapies. Metastases are 
encountered in over half of patients with renal cancer, drastically reducing 
their life expectancy. Even with new specifically directed molecularly 
targeted therapies, the median survival of metastasizing CCRCC is less than 
one year.   
Orellanine is a nephrotoxin found in fungi, and sometimes ingested 
accidentally. The ingestion of the fungi leads to renal failure and disruption 
of the proximal tubular cells. Interestingly, CCRCC originate from this cell 
type. Our hypothesis is that since proximal tubular cells in the kidney 
selectively take up orellanine, cancer cells in metastases of the same origin 
would also do so. This may give rise to a potentially curative therapy against 
metastasizing CCRCC.  The aim of the thesis is to 1) Determine the efficacy 
of orellanine as a targeted therapy against clear cell renal cell carcinoma in 
vitro and in vivo 2) Establish a robust technique for detection of orellanine in 
plasma 3) Evaluate the long-term effects in patients after accidental intake of 
mushrooms containing orellanine. 
We could demonstrate that orellanine induces dose-dependent cell death in a 
number of CCRCC cells while cells from other areas of the body remained 
unharmed. When we treated human CCRCC xenografts in nude rats with 
orellanine, the tumor cell mass was significantly reduced within a few days, 
featuring large apoptotic and necrotic areas. We could also detect orellanine 
with our newly developed analysis method in minute concentrations. This is 
necessary for monitoring orellanine concentrations in the body in a possible 
future clinical trial. The specificity for renal cells was evident in our study of 
the long-term outcome after accidental intake of orellanine-containing 
mushrooms. In these patients, we could not detect any difference in mortality 
or morbidity compared to age- and sex-matched controls. 
In conclusion, this thesis shows that orellanine is indeed highly toxic to 
CCRCC cells both in vitro and in vivo. Orellanine seems to be highly kidney-
specific with no long-term effects other than renal failure, which can be well 
dealt with using dialysis or renal transplantation. Orellanine thus has 
potential to become a new potentially curative treatment of metastatic 
CCRCC. 
Njurcancer drabbar över 100000 personer i världen och runt 1000 personer i 
Sverige varje år. Det finns flera olika sorters njurcancer, och klarcellig 
njurcancer är den vanligaste sorten (ca 75%). Om tumören hittas i tid kan den 
opereras bort från njuren med god prognos, men om den hunnit bilda 
dottersvulster i andra delar av kroppen (ca 60% av patienterna drabbas) är 
prognosen kraftigt försämrad. I dagsläget finns det ingen botande behandling 
för dessa patienter och hälften av dem dör inom ett år, trots behandling med 
nya molekylära målsökande terapier. 
Klarcellig njurcancer har sitt ursprung i en specifik celltyp av njuren som 
kallas proximala tubuli. Svampgiftet orellanin, som återfinns i toppig 
giftspindling (som ibland förväxlas med trattkantareller), dödar specifikt 
dessa celler. Frågeställningen i avhandlingen är om orellanin också kan döda 
cellerna i metastaserna då de är av samma ursprung. Då skulle svampgiftet 
kunna användas som botande behandling av denna cancerform. 
Våra studier visar att orellanin är starkt toxiskt mot klarcellig njurcancer både 
i cellodling och i en experimentell tumörmodell av human klarcellig 
njurcancer. Behandling av tumörerna med orellanin minskar tumörens vikt 
och andelen levande tumörceller minskar drastiskt. För att eventuellt kunna 
utnyttja orellanin terapeutiskt måste man kunna följa halten av orellanin i 
människa och djur noggrant. Därför etablerade vi en ny och mycket känslig 
metod för mätning av orellanin, baserad på masspektrometri, där vi kan mäta 
koncentrationer av orellanin som är lägre än en promille av den effektiva dos 
som förstör njurcancerceller. Orellanin tycks inte orsaka skador i några andra 
organ utan drabbar specifikt njurceller. Vi såg till exempel inte någon ökad 
sjuklighet hos patienter upp till 30 år efter oavsiktlig förgiftning med 
orellanin-innehållande svamp jämfört med ålders- och könsmatchade 
kontroller. Detta tyder på små eller inga biverkningar på andra organ än 
njuren vid cancerbehandling med orellanin. 
Sammantaget har orellanin potential för att vara en botande behandling av 
spridd klarcellig njurcancer. Den njursvikt som orellanin skulle ge som 
biverkan kan framgångsrikt behandlas under lång tid med modern dialys eller 
njurtransplantation. 
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Cancer induces 12.6 million new cases per year in the world and further 
causes 7.6 million deaths annually, thus rendering it as the second most 
common cause of mortality, after heart and cardiovascular events.
1
  The 
hallmarks of cancer are; growth stimulation, resistance to growth-inhibitory 
signals, unlimited ability to divide, promoted angiogenesis, resistance 
towards apoptotic signals and metastatic capacity.
2
  The prognosis varies for 
different cancer types as well as different subgroups within a distinct cancer 
form. Overall, the prognosis is impaired when the cancer has metastasized. 
Renal cancer claims 116,000 deaths per year worldwide
1
 and is notorious for 
its high metastatic frequency and high resistance to chemo-
3
 and 
radiotherapy.
4
 Hence, patients with metastatic renal cancer have a truly poor 
prognosis. The lack of curative treatment results in a median survival of only 
10 months.
5
  
This thesis describes the initial evaluation of a fundamentally new 
experimental treatment against renal cancer, with actual curative potential. It 
originates from the discovery that low concentrations of the fungal 
nephrotoxin, orellanine, occurring naturally in several Webcap species, has a 
remarkable, previously unknown ability to kill cells of a specific subtype of 
renal cell carcinomas and metastases. Other cell types are unaffected. In the 
introduction section, various aspects of renal cancer, as well as the mode of 
action of orellanine, will be covered in some detail. 
 
The kidneys are the organs in the body responsible for long-term acid-base 
balance, maintenance of water and electrolyte balance, osmolarity regulation, 
hormonal production including erythropoietin, elimination of metabolic 
waste products, and excretion of exogenous water-soluble compounds. The 
urine volume produced daily through the capillaries in the glomerulus is 180 
liters. Due to the reabsorption in the tubular compartments, the final urine 
leaving the body is approximately 1.5 liters. All of the essential procedures in 
the kidney take place in the nephron, which is the smallest functional unit of 
the kidney. 90% of the nephrons are located in the cortical, outer part of the 
kidney. The nephron consists of a capillary tuft, called the glomerulus, 
surrounded by Bowman’s capsule, which is connected to a convoluted 
tubular part. The glomerular cell components represent approximately 5% of 
the cortex in kidney, whilst the remaining 95% have a tubular origin. Each 
kidney contains approximately one million nephrons. 
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Figure 1. Illustration of a nephron. Modified from University of Michigan 
(open.michigan,http://open.umich.edu, Urinary tract) 
 
The glomerular filtration barrier is similar to a highly selective sieve, highly 
permeable for water, electrolytes and small molecules, while normally 
completely preventing blood cells and proteins from passage. The glomerular 
barrier is composed of four specific layers from blood to urine: The 
endothelial cell surface layer (ESL), the fenestrated endothelial cell, the 
glomerular basement membrane (GBM) and the podocyte with its slit 
membrane.
6
  
The ESL is a gel-like structure lining the endothelial walls in the glomerulus. 
It consists of two components; the glycocalyx, which is covalently bound to 
the endothelial cells, and the more loosely attached endothelial cell coat.
7
 The 
ESL is composed of a variety of molecules (e.g. proteoglycans and 
glycoproteins). It is highly negatively charged, and the charge is believed to 
be a requirement for the permselective properties of the filtration barrier.
8
  
8 
The endothelial cells of the glomerular capillaries are distinguishable from 
other endothelial cells, due to their abundant fenestrations. The fenestrae 
cover 30-50% of the glomerular endothelial surface.
9
 They are 60-80 nm in 
diameter and would be permeable for plasma proteins, like albumin, if the 
endothelial cells and the fenestrae were not covered by the ESL, which acts 
like a plug.
10,11
 The glomerular basement membrane provides adjacent cells 
with attachment support. On the vascular side, the endothelial cells are 
attached to the GBM and the podocytes are attached on the other side, facing 
the urinary space. The GBM also functions as a barrier to prevent filtration of 
macromolecules.
12,13
 Interestingly, the GBM is built up by components 
produced by the endothelial cells and the podocytes, like laminin and 
collagen type IV.
12,14
   
The “outermost” layer in the glomerulus is made up by epithelial cells 
(podocytes). This specialized cell has a large cell body with foot processes 
that encircle the GBM and the entire glomerulus. The small gaps between the 
foot processes are called slit diaphragms. The slit diaphragm is stabilized by 
several proteins important for the filtration integrity of the glomerulus, like 
nephrin, podocin and CD2AP. 
15
  
 
The tubular compartment is anatomically divided into the proximal tubular 
region, the loop of Henle, the distal tubulus and finally the collecting duct, 
discharging the urine into the renal pelvis. The proximal region and the loop 
of Henle are each about 15mm in length, while the distal tubules are shorter 
(3-4 mm). The majority (2/3) of the urine produced by glomerular filtration is 
reabsorbed across the proximal tubular cells, amounting to 120 liters per day. 
Water moves through water channels (aquaporins), or paracellularly driven 
by the crystalloid-osmotic pressure created by the Na-K-ATPase situated on 
the basolateral side of the proximal tubular cells, facing the peritubular 
capillaries. A multitude of vital solutes are taken back from the urinary space 
together with sodium through selective transporters driven by the sodium 
concentration gradient. Several other ions are readily reabsorbed in the 
proximal tubular segment, like Cl
-
 and Ca
2+
.
16
 Other substances being 
reabsorbed to more than 99% are glucose, amino acids, and bicarbonate. 
Other inorganic ions (e.g. phosphate) and organic acid metabolites are also 
reabsorbed to a large extent.
17
  Some selective transporters will be described 
in detail below. The proximal tubular cells also reabsorb sodium via the 
Na
+
/H
+
-exchanger 3 (NH3).
16
 The sodium reabsorbed into the proximal 
tubular cells must exit the cell on the abluminal side, against its 
electrochemical gradient, to maintain the sodium concentration gradient 
 9 
across the cell membrane and hence the sodium-dependent luminal 
reabsorption. This is made possible by abundant quantities of Na
+
-K
+
-
ATPase, requiring constant and abundant supply of energy, which is why the 
proximal tubular cells are densely populated with mitochondria. Thus, the 
proximal tubular cells are metabolically very active and have a high oxygen 
consumption.  
In this context, it is not surprising that the proximal tubular cells are highly 
susceptible to ischemia. It has been shown that loss, malfunction, or death of 
these cells is the main cause behind acute kidney injury (AKI). When 
proximal tubular cells are dying or malfunctioning, they lose their polarity, 
Na-K-ATPase becomes evenly distributed all over the cell surface, 
directional sodium transport ceases and fluid cannot be reabsorbed. 
18
 
Several pathophysiological conditions involve the proximal tubular cells. 
One example is the Fanconi syndrome, which is a generalized concept for the 
dysfunction of the reabsorption in the proximal tubules.
19
 A patient with 
Fanconi syndrome loses glucose, vitamins, amino acids, proteins and other 
important substances via the urine due to impaired tubular re-uptake.  
In this thesis, I have studied a substance that is thought to be specifically and 
selectively taken up by proximal tubular cells. It is therefore prudent to 
discuss in more detail some of their known transporters. There are two main 
superfamilies of transporter proteins: the ATP binding cassette (ABC) 
transporters and the solute carriers (SLC). 
20
 Within the latter family, a huge 
variety of substrates are being transported; organic and inorganic cations and 
anions, amino acids, vitamins, glucose, urea and lipids among several others. 
21
 The proximal tubular cells are rich in a variety of transporters. Below, a 
few are mentioned. 
Glucose reabsorption and transportation back to the blood is performed by 
sodium glucose transporters (SGLT) and glucose transporters (GLUT). 
Glucose is filtered freely through the glomerulus and with a plasma 
concentration of 5 mM, or 1 g/l, about 180 grams is filtered each day. Due to 
the effective reabsorption of glucose in the proximal tubules, almost no 
glucose is eliminated via the urine. Glucose is mainly reabsorbed in the first 
segment (S1) through a sodium co-transporter, sodium glucose transporter 2 
(SGLT-2), which reabsorbs 90% of the glucose. Further down the tubular 
segment, SGLT-1 reabsorbs the remaining 10%. 
22
 Glucose transporter 2 
10 
(GLUT-2) excretes glucose from the proximal tubular cell to the interstitium 
on the blood-side. 
23
 
The organic anion transporter (OAT) family belongs to the SLC superfamily 
of transporters. They are responsible for uptake and elimination of a variety 
of organic anionic substances, (e.g. drugs and metabolites) in the proximal 
tubular cells in the kidney. They are localized either on the apical or 
basolateral membrane of the proximal epithelial cell and are often working in 
cooperation. OAT1 and OAT3 are situated on the basolateral side, 
transporting drugs from the blood stream into the proximal tubular cells and 
dicarboxylate in the opposite direction.
24,25
 They are also responsible for 
uptake of glutathione.
26
 On the apical membrane, OAT4 and NST/URAT 
eliminates substances from within the cell in combination with reabsorption 
of certain substances from the urine.
24
 OAT4 exchanges organic anions from 
the urine with dicarboxylate, while URAT1 reabsorbs urate from the lumen 
and elimintates anions.
25
 Hence, the proximal tubular cells eliminate drugs by 
extracting them from the blood and extruding them into the urine and thus 
eliminating them from the body. Drugs that are thought to be eliminated in 
this manner are numerous, like penicillin, statins, antiviral drugs, loop 
diuretics, and non-steroid anti-inflammatory drugs (NSAIDs).
24,27
 Examples 
of metabolites are p-aminohippurate (PAH) and prostaglandin E2.
28
   
The multidrug resistant proteins were initially discovered in cancer cells, 
highly resistant to chemotherapeutic agents 
29
. They belong to the ABC 
superfamily. MRP2
30
 and MRP4 have been localized to the apical membrane 
of the proximal tubules while MRP6 is found basolaterally.
31
 MRP2 is 
responsible for excretion of anti-neoplastic drugs like vinblastine, 
adriamycin, antiviral compounds and other organic anions into the urine.
25
   
MRP4 transport cAMP, cGMP and urate into the lumen. The function of  
MRP6 remains elusive.
31,32
    
The organic cation transporters (OCTs) are members of the SLC family. 
There are several members in the OCT family, but so far OCT1 has been 
shown to be present on the apical membrane of human proximal tubular 
cells
33
 and OCT 2 on the basolateral membrane.
34
 OCT2 transports cations 
 11 
from the interstitium into the proximal cells while OCT1 performs the same 
task on the apical membrane and it is thought to among other substances 
reabsorb metmorfin from the urine. Both transporters mediate the uptake of 
tetraethylammonium (TEA) and 1-methyl-4-phenylpyridinum (MPP) among 
other organic cations.
34
  
Another family within the SLC family is the multidrug and toxin extrusion 
(MATE) transporters. MATE1 and MATE2-K are found on the apical 
membrane in proximal tubular cells. They are H+/organic cation antiporters, 
transporting H
+
 along its concentration gradient into the cell and extruding 
organic cations into the lumen. They extrude the TEA and MPP, taken up by 
the OCTs. They also transport creatinine, guanidine and estrone sulfate to the 
urinary space.
35
  
An additional organic cation transporter is P-Glycoprotein (also known as 
MDR1), a member of the ABC super family.
29
 Like the MRP family, P-
glycoprotein (P-gp) was first identified as a drug extruder in cancer cells. It is 
located on the apical membrane of proximal tubular cells,
36
 where it excretes 
drugs such as taxol and steroids into the urine and other organic cations. 
31
 
Although the glomerular filtration restricts proteins from being filtered into 
the urine, small amount of plasma proteins such as albumin actually do pass 
into the urine. Most of these proteins are however recovered in proximal 
tubular cells by megalin
37
 and cubilin
38
 receptor endocytosis. The receptors 
are present at the apical membrane and bind a diversity of different 
substances. 
37
 Megalin in combination with cubilin binds to practically all 
proteins, like albumin, insulin, apolipoproteins and vitamin-associated 
proteins. 
39
 Megalin is the transmembrane protein of the two and hence 
responsible for endocytosis of the bound compounds of cubilin. Another 
protein, amnioless, is required for the normal function of cubilin.
37
 When 
internalized, the vesicle is transported to the lysozyme, in which proteins are 
degraded to amino acids and are returned to the circulation with the vitamins. 
The megalin and cubilin receptors are transported back to the apical 
membrane in a process requiring a specific chloride channel ClC-5.
37,39,40
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Figure 2.  Some of the transporters of the proximal tubular cell in the kidney. 
 
With an incidence of about 2 % of all solid tumors, cancer of the kidney is 
not as common as breast or prostate cancer. However, it still claims 116,000 
lives every year out of the 274,000 new cases diagnosed worldwide.
1
 The 
most common form of renal cancer is the conventional (clear cell) renal cell 
carcinoma (CCRCC). It constitutes 75% of all renal carcinomas. The 
remainder is distributed between papillary renal carcinoma (10-15%), 
chromophobe renal cell carcinoma (5%), collective duct carcinoma (1%) and 
unclassified renal carcinoma (3-5%), according to the Heidelberg 
classification from 1996
41
. Sarcomatoid appearance may be present in all of 
the subtypes of renal cancer, and is a hallmark for high transformation
41
 
Furthermore, it is associated with a worse prognosis.
42,43
 The absolute 
majority of renal cancers are formed from cells in the tubular system in the 
kidney. Wilms’ tumor is an exception, since it seems to originate from the 
glomerular podocyte that express the same Wilms’ tumor (WT) antigen. 
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The global distribution of renal cancer varies, with the highest incidence in 
Europe, North America and Australia. In Sweden, the trend is a slight 
decrease over the last decade.
44
 In contrast, incidence is rising in the United 
States.
45
 In general, there is a male predominance of 2:1.  Smoking is an 
established, dose-dependent risk factor for renal cell carcinoma (RCC).
46-48
 
Obesity and hypertension have also been shown to be risk factors for RCC
49-
51
, while fruits and vegetables are believed to have a protective effect.
52
 The 
average age at diagnosis and surgery is 61 years.
53
 Overall survival varies 
with tumor status at diagnosis. Patients with local tumors at diagnosis, status 
T1 or T2 (please see Appendix for tumor staging), have a 5-year survival of 
over 80%.
54
 
55
 Furthermore, the prognosis and survival also vary with specific 
subtypes of RCC, with a worse prognosis for CCRCC compared to papillary 
RCC for T1 and T2 tumors.
56
 If the cancer has metastasized, the prognosis is 
significantly impaired.  
 
Renal carcinoma is generally asymptomatic and the disease is typically 
discovered incidentally. The most common clinical manifestation is 
macroscopic hematuria, which is present in approximately 40% of the 
patients.
57
 Previously, a classic triad of symptoms was expected by the 
clinicians namely hematuria, flank pain and a palpable tumor. However, these 
three symptoms combined occur only in a minority of the patients, less than 
10%, and usually at an advanced state of the disease.
58
 With the evolution of 
sophisticated detection techniques (e.g. computed tomography), tumor 
discovery has improved during the last decades.
59
 This leads to tumors being 
detected at an earlier stage, and concomitantly less than 1% of cases are 
currently diagnosed by the classic triad.
60
 The symptoms of renal carcinoma 
differ notably between patients and are often diffuse. Examples of clinical 
indications displayed during renal carcinoma include hematuria, fever, flank 
pain, weight loss, hypercalcemia, anemia, hypertension, loin pain and hepatic 
dysfunction, all of which could be indicative of a variety of disorders.  
Renal cancer, including renal cell carcinoma, is classified according to the 
TNM staging system. This system serves as a guide for treatment as well as 
for the prediction of patient outcome. Please refer to Appendix for details of 
the classification. 
14 
 
The sole curative treatment of renal cell carcinoma available today, is 
surgical removal of the entire tumor mass if it is localized to the kidney.
61
 
This can be achieved either by radical nephrectomy (RN), i.e. removal of the 
entire kidney, or by nephron-saving surgery (NSS). Nephron-saving surgery 
has been shown to be equally good in terms of overall survival for renal 
cancers for tumors fully localized to the kidney and smaller than 4 cm. Thus 
NSS is the recommended procedure for this tumor size.
62
   
 
The prognosis for patients with metastasis at diagnosis is significantly 
reduced; the 5-year survival is less than 10%.
54,55
 Approximately 30% of the 
patients have an advanced disease at diagnosis and furthermore one third with 
localized tumor initially will subsequently develop metastases.
54
 
63
 The most 
common metastatic site is the lungs, followed by bone, lymph node, liver, 
adrenal gland and brain (see Table 1).
64
  
If the metastatic lesion is limited, it can be excised as adjuvant therapy. This 
has mostly been applied to lung metastases, where the 5 year survival is 40% 
after complete resection.
65
 However, in most patients, metastatectomy is 
performed mainly for musculoskeletal integrity or pain control.
66
   
Two prospective randomized trials have shown an improvement of median 
survival time in patients with metastatic disease submitted to cytoreductive 
nephrectomy, (i.e. removal of the primary tumor), followed by interferon-α 
(IFN-α) treatment, compared to patients receiving IFN-α treatment alone. In 
the studies, the median survival in the surgery plus IFN group was 17.4 
versus 11.7 months and 17 versus 7 months, respectively.
67,68
 In combination, 
these trials showed an improvement of median survival of 13.6 over 7.8 
months, which was statistically significant.
69
 This has however, not been 
studied in other systemic treatment strategies, (e.g. targeted therapies) of 
mRCC.
70
 In less than 1%, metastases (lung metastases most frequently) have 
gone through spontaneous remission, typically after the excision of the 
primary tumor.
71,72
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Metastatic 
sites      
  
   
  
  Site   %   
  Lung 
 
45   
  Bone 
 
30   
  Lymph node 22   
  Liver 
 
20   
  Adrenal 
 
9   
  Brain 
 
8   
  Other 
 
8   
          
Table 1. Distribution of renal cancer metastases sites. 
 
 
Standard treatments of cancer (i.e. chemotherapy 
3
 and radiation therapy),  
are generally ineffective against renal cell carcinoma.
4,73
 Immunotherapy 
have been the standard care of mRCC for the last decades. Targeted therapies 
have emerged during the last 10 years, providing an increase in progression 
free survival (PFS) and a few months extended overall survival (OS). They 
are discussed briefly below. 
In immunotherapy using cytokines, the object is to stimulate tumor-
infiltrating lymphocytes and natural killer cells to react against the tumor 
cells.
74
 The two main candidates used as treatment for mRCC are interferon-α 
(IFN- α) and interleukin-2 (IL-2). 
IFN-alpha was explored early as treatment in combination with vinblastine 
chemotherapy. The combination of IFN-alpha and vinblastine compared to 
vinblastine alone had a significant effect in median survival (67.6 versus 37.8 
weeks).
75
 Subsequent studies, comparing IFN-alpha alone against a 
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combination of IFN-alpha and vinblastine showed no increased benefit for 
the combination; hence IFN-alpha was considered solely responsible for the 
survival benefit. A Cochrane review, from 2005, showed increased overall 
survival in IFN-alpha treated patients compared to control. The one-year 
mortality odds ratio (OR) was 0.56 [0.40, 0.77] for the pooled studies of 615 
patients.
76
 However, survival benefits were generally modest for IFN-alpha. 
Interleukin 2 (IL-2) was the first treatment approved by the food and drug 
administration (FDA) for treatment of mRCC. In a clinical trial with 255 
patients, high dose IL-2 induced a complete response in 5% of the patients 
and partial response in 9%. However, performance status was a predictive 
factor of the response to IL-2 and severe side effects were reported. In total, 
4% of the patients died, likely due to the treatment, reflecting a relatively 
high toxicity for high dose Il-2.
77
 When reducing the dose to 90% of the high 
dose, reduction of severe side effects was observed. The response rate was 
significantly higher in the high-dose patients compared to low-dose (21% vs. 
13%). However, in terms of overall survival no significant results were 
obtained. Using low dose, interleukin 2, administered subcutaneously, instead 
of intravenously, further reduced the side effects observed, with similar 
response rates.
78
 In the Cochrane review from 2005, a slight benefit for IFN-
alpha over low dose IL-2 was seen (0.93 [ 0.66, 1.31 ]).
76
 However, there are 
no studies comparing the two cytokines, using high IL-2, in analysis in 
overall survival. 
Since the detection of the von-Hippel Lindau (VHL) protein in clear cell 
renal cell carcinoma (please see section below), therapies targeting the 
molecular pathways activated during VHL-deficiency have emerged. Mainly, 
these therapies affect neo-vascularization by inhibiting either vascular 
endothelial growth factor (VEGF) or its receptor VEGF-receptor (VEGFR). 
Sorafenib acts by inhibiting the VEGFR-2 and 3 and platelet derived growth 
factor receptor (PDGFR). It also targets RAF signaling, thus inhibiting both 
angiogenesis together with proliferation.
79
 It has been shown to induce longer 
progression-free survival in IFN-a drop out patients, but has so far not been 
able to produce increased overall survival (OS). Combinatory studies, using 
Sorafenib and IFN-alpha at low doses, have also been ineffective.
80
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Sunitinib targets the VEGFR and PDGFR.
81
 In a clinical phase III trial, 
Sunitinib increased progression free survival compared to IFN-alpha with 6 
months (11 vs. 5) and overall survival with 4.6 months (26.4 vs. 21.8). Both 
Sunitinib and Sorafenib have significant side effects, including hypertension, 
fatigue, and diarrhea.
82
  
Bevacizumab is a monoclonal antibody, directed against soluble VEGF.
83
  In 
a phase III trial, combining bevacizumab with IFN-alpha versus IFN-alpha 
and placebo, a progression free survival benefit was observed in the 
bevacizumab arm (10.2 vs. 5.4 months). OS was not possible to assess. 
Known side effects of bevacizumab include proteinuria, bleeding and 
hypertension.
84
   
Axitinib is an inhibitor of the VEGF-receptors.
85
 In a phase III trial, axitinib 
was compared to sorafenib, as a second line treatment. Results showed 
increased progression free survival in the axitinib arm (6.7 vs. 4.7 months). 
Side effects of axitinib are diarrhea, fatigue and hypertension.
86
  
Pazopanib blocks the VEGRF, PDGFR and c-Kit.
87
 A phase II trial of 
pazopanib versus placebo showed a tendency to increase in OS for pazopanib 
(22.9 vs. 20.5 months). This was not significant, though, probably due to 
crossover from the placebo arm to the treatment arm. Side effects reported 
where diarrhea, hypertension and liver abnormalities.
88
  
Tivozanib inhibits the VEGFR.
89
 In a phase III study, tivozanib was 
evaluated as a first or second line treatment versus sorafenib. Previous 
treatment with VEGF/VEGFR or mTOR inhibitors was not allowed. PFS was 
significantly longer in the tivozanib group (11.9 vs. 9.1 months). In terms of 
overall survival, sorafenib did show slightly increased survival (29.3 vs. 
28.8), but it did not reach statistical significance. Side effects for tivozanib 
(e.g. hypertension) were more common compared to sorafenib.
90
  
The mammalian target of rapamycin (mTOR) is participating in proliferation 
in cells by activating AKT/PI3 kinase pathway. By inhibiting mTOR, 
proliferation is impaired and it has been shown that blocking of mTOR 
activity also reduces the amount of HIF-α and VEGF.91  
18 
Temsirolimus efficacy on renal cell carcinoma was assesses in untreated, 
poor risk patience, versus IFN-α and IFN-α and temsirolimus. Temsirolmus 
alone had the best OS with 10.9 months versus 7.3 months for IFN-α and 8.3 
for IFN- α plus temsirolimus. In the combination group, both the IFN-α and 
the temsirolimus dose were lower than in the single treatment groups. 
Reported side-effects for temsirolimus are rash, peripheral edema, 
hyperglycemia and hyperlipidemia.
92
  
Everolimus versus placebo was evaluated in a phase III trial, as secondary 
treatment after progression post VEGRF treatment. PFS was 4.9 months for 
everolimus versus 1.9 months for placebo. Overall survival did not show any 
significant effect (14.8 vs. 14.4 months). This might be due to 80% cross-
over of the patients from the placebo arm to the everolimus arm. Side effects 
reported were infection, dyspnea and fatigue.
93
  
Vaccine therapy is a new type of therapy explored within the cancer field 
during the last decade. There are several different types of vaccines including  
whole tumor vaccines, peptide vaccines, dendritic cell vaccines, DNA-
vaccines
94
 and viral vector vaccines.
95
 In general, they exploit the fact that 
tumors express antigens not present on normal tissues. The vaccine directs 
the body’s immune system to destroy these tumor-associated antigen-
presenting cells. Several vaccines’ efficacy has been explored in clinical 
trials. For a dendritic cell vaccine, AGS-003, a phase III study is planned for 
mRCC patients, in combination with sunitinib.
96
 Two additional different 
vaccines are discussed below. 
In a phase II trial on mRCC patients using a viral vector, the modified 
vaccine Ankara (MVA-5T4), with or without IFN-α, the vaccine treatment 
alone showed promising results in an increased OS (18.3 vs 5.9 months).
97
 
However, in a following phase III trial, with combination of MVA, plus IL-2, 
no difference in OS was achieved 20.1 vs. 19.2 months.
98
 The vaccine was 
well tolerated and the only adverse side effect reported was soreness at the 
injection site.
99
  
The use of a multi-peptide vaccine, IMA901, consisting of 10 different 
tumor-associated peptides, was investigated in a phase II trial of mRCC. 
Patients, progressing on prior systemic treatment, were treated with IMA-901 
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with or without a single-dose cyclophosphamide (Cy). Cy was used with the 
intention to reduce the amount of regulatory T-cells. Results showed a trend 
towards increased OS in the combinatory group, (23.5 vs. 14.8 months). The 
effect could, however, not be contributed to Cy alone, since in the non-
responder patients, the OS did not differ between the two treatments.
100
 A 
phase III trial on mRCC patients is ongoing where IMA901 is combined with 
sunitinib.
101
   
 
 
The most common form of renal cancer is called conventional, or clear cell, 
renal cell carcinoma (CCRCC). It originates from the proximal tubular 
epithelial cells in the kidney
102,103
, although a more distal origin has been 
proposed.
104
 The histologic appearance is characterized of a clear cytoplasm, 
due to a high lipid and glycogen content.
105,106
  
Clear cell renal cell carcinoma form has the worst prognosis of the three most 
common RCCs; i.e. clear cell, papillary and chromophobe RCC.
56
 This is true 
especially for smaller tumor sizes (T1 and T2). The metastatic frequency is 
also higher for clear cell carcinomas. The 5-year overall survival is 50% for 
clear cell carcinoma 
56
 and for the patient groups presenting an advancement 
of the disease at diagnosis it is less than 5% with a median survival of 6-10 
months for this patient group.
55
 When a sarcomatoid component is present, 
the prognosis is even further impaired, since sarcomatoid CCRCC has been 
shown to be substantially more proliferative and displays a mesenchymal 
phenotype.
107
 
Several cancer forms, among them CCRCC, is common in familial von 
Hippel-Lindau (VHL) disease. A molecular marker for the disease is a germ 
line mutation harbored in the tumor suppressor VHL gene.
108,109
 The gene 
was first identified in 1993 on chromosome 3p25-p26.
110
 In sporadic forms of 
CCRCC, the VHL-protein (pVHL) is frequently inactivated.
111-113
 Loss of 
pVHL have not been shown to be sufficient for development of cancer on its 
own, it rather requires other genetic modifications.
114,115
 However, patients 
with VHL syndrome develop renal cancer or cysts at a median age of 39 
years.
116
  
The pVHL is involved in degradation of the α-subunit of hypoxia inducible 
factor (HIF-α). At normoxia, HIF-α is hydroxylated, marking it for 
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ubiquitination by pVHL and hence degradation. At hypoxic conditions, or 
when pVHL is inactivated, hydroxylation does not take place, thus stabilizing 
HIF-α and promoting its dimerization with HIF-β. The active HIF-complex 
translocates into the nucleus, acting as a transcription factor to promote gene 
expression for a variety of genes including vascular endothelial growth factor 
(VEGF), platelet-derived growth factor (PDGF), tumor growth factor alpha 
(TGF-α) and glucose transporter 1 (GLUT-1). This promotes angiogenesis, 
cellular progression, metastasis and increased glucose metabolism. Loss of 
VHL thus has a considerable impact on the tumor genesis of CCRCC and 
gives rise to highly vascularized tumors.
109,117
  
Abnormal levels of HIF-1α have also been shown to be partly responsible for 
the high lipid accumulation in clear-cell renal cancer cells, due to increased 
expression of very low-density lipoprotein receptors (VLDL-R). A partial 
knock-down of HIF-1α or VLDL-R, reduced the lipid accumulation.118  
Defects or loss of VHL leads to increased secretion of transforming growth 
factor β (TGF-β) and sensitivity to TGF-stimuli in clear cell renal cancer 
cells. Augmented TGF-signaling correlates with worse prognosis. 
Interestingly, patients with metastatic CCRCC present with increased TGF-
activity.
119
 Genetic mapping have shown extensive overlapping of the HIF 
and TGF-β signaling pathways, indicating a cross-talk between the two 
pathways.
120
 
 
Orellanine is the toxin responsible for the intoxication subsequent to 
ingestion of fool’s webcap (Cortinarius Orellanus) or deadly webcap 
(Cortinarius Rubellus formerly called Cortinarius Speciossiumus). The 
toxicity of these toadstools was first detected by Grzymala
121
 after a mass 
poisoning in Poland in 1952, where over 100 people were affected. Grzymala 
also isolated, characterized and named the toxin in 1962.
122
 The chemical 
structure was revealed in 1979, by Antkowiak and Gessner,
123
 to be 3,3’,4,4’-
tetrahydroxy-2-2’-bipyridine-N-N’-dioxide. Further, it was synthetsized in 
1985.
124
 Orellanine is photosensitive and decomposes when exposed to UV-
light into orellinine and orelline. The former is also nephrotoxic whilst the 
latter is non-toxic.
125
 Orellanine-containing mushrooms are distributed both 
in Europe and North America, with Cortinarius Rubellus being more 
frequent in Northern part of Europe (i.e. Scandinavia) and Cortinarius 
Orellanus in the central and Southern parts.
126
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Figure 3. The structures of orellanine, orellinine and orelline, respectively. 
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12h to14 days. In general, a longer incubation phase is associated with a 
better prognosis. Of 90 intoxication cases, reviewed by Danel et al, about one 
third of the patients developed chronic renal insufficiency. The remaining 
patients regained their kidney function within weeks to months.
127
 The toxin 
effect is dose-dependent, but there is considerable individual variation in 
sensitivity.
128
 This has been confirmed also in animal studies.
126,129
 Holmdahl 
developed an index to predict the prognosis, based on the creatinine level in 
relation to the days since the mushroom ingestion.
126
 For patients with end 
stage renal failure, lifelong dialysis will be necessary, unless kidney 
transplantation is an option. 
 
The clinical symptoms of patients suffering from orellanine intoxication are 
similar to those seen in animal studies. Characteristics are tubulo-interstitial 
damage with edema and infiltration of immune cells.
126,130-132
 More careful 
histological examinations have revealed that it is the proximal tubular cells in 
the kidney that are affected by orellanine.
132,133
 The toxin is believed to be 
taken up selectively by the proximal tubular cells and is thought to be 
sequestered there.
134
 Orellanine has been reported in kidney biopsies as long 
as 6 months after ingestion.
131
 However, orellanine cannot be detected in 
plasma or urine and after the manifestation of clinical symptoms it is found 
exclusively in the kidneys.
134
  
The mode of action of orellanine remains somewhat elusive. It is clear that 
orellanine causes increased oxidative stress, both in vitro
135
 and in vivo,
136
 
and markedly down-regulates the oxidative stress defense.
136
 Also, inhibition 
of protein synthesis have been reported.
137
 Antioxidant therapy using N-
acetylcystein (NAC) in patients after orellanine intoxication has been tried in 
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a few patients.
138,139
 They presented with mild (n=2) to intermediate (n=1) 
intoxication symptoms when scored according to the Cortinarius 
NephroToxicity Index (CNT).
126
 All of the three patients recovered, two 
where dialysis dependent during a treatment period and one never required 
dialysis. Hence, the evidence regarding the possible benefit of NAC after 
orellanine intoxication is inconclusive. 
 
Reactive oxygen species (ROS) is produced in the cells normally as a by-
product of cellular metabolism.
140
 It may also act as a messenger in signaling 
pathways.
141
 There is a strict balance of the ROS-levels and the antioxidant 
defense in the cell.  Uncontrolled ROS levels, produces oxidative stress and 
may induce severe damage. This may induce oxidation of lipids, proteins and 
DNA.
142
 Also mitochondrial DNA is susceptible to oxidative damage. 
143
 The 
damages may induce cell death in form of apoptosis or necrosis.
144
  
Interestingly, in cancer cells, the oxidative stress is increased together with 
anti-oxidative defense.
143
 Hence, the oxidative level in these cells is higher 
compared to the reducing level, which is the contrary in normal cells. The 
most common oxidative stress radical is the superoxide anion (O2
-
), formed 
from oxygen by an electron addition. The anti-oxidant enzyme, superoxide 
dismutase (SOD) catalyzes the reaction of the superoxide anion to the non-
radical but still a ROS-molecule; hydrogen peroxide (H2O2). This is further 
converted to water by another important anti-oxidant enzyme, namely 
catalase (CAT).
141
  
 
Induction of apoptosis has a central role in cancer treatment strategies as an 
effort to kill the tumor and overcome the resistance to apoptosis which is 
typical in cancer.
145
 Apoptosis has a normal role in cells during development 
and homeostasis.
146
  However, it may also be induced as a response to severe 
stress or damage of the cell, like elevated ROS-levels.
144
 Apoptosis is 
characterized by cell shrinkage, chromatin condensation, DNA-fragmentation 
and membrane blebbing. The cell forms apoptotic bodies, containing 
organelles and nuclear fragments surrounded by plasma membrane, that are 
phagocytized by macrophages, parenchymal cells or neoplastic cells and 
subsequently degraded.
147
  
Apoptotic signaling is divided into two pathways: the intrinsic and the 
extrinsic pathway. The previous is activated within the cell whilst the latter is 
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activated from the outside. The main players in apoptotic signaling are the 
caspases. These are proteins with protease activity that cleave a number of 
target proteins.
148
 There are two types of caspases: initiator and effector 
caspases, taking part in the initial activation and the finalization of apoptosis 
respectively. There are distinct caspases for the intrinsic and the extrinsic 
pathways. However the two pathways converge in the activation of the 
effector caspases 3, 6 and 7. Below, the two pathways will be described. 
 
The intrinsic pathway is activated as a response to severe intracellular stress 
like DNA-damage, hypoxia and oxidative stress. This triggers the activation 
of the tumor suppressor protein, p53, which activates proteins that trigger the 
release of SMAC/DIABLO and cytochrome C from the mitochondrion into 
the cytosol.  SMAC/DIABLO binds to and thus prevents inhibitor proteins of 
apoptosis (IPA) to inhibit caspases. Cytochrome C binds to an adaptor 
protein, APAF1, and this complex, called the apoptome, activates one of the 
initiator caspases, caspase-9. Caspase-9 initiates a caspase cascade by the 
activation of the effector caspases 3, 6 and 7 that will execute apoptosis. 
149
  
 
The extrinsic pathway is activated by ligand binding to a death receptor at the 
cell’s plasma membrane. There are several receptor members in this tumor 
necrosis factor (TNF) family. The most well-known are: Fas, TNF-receptor 
(TNFR) and TNF-related apoptosis-inducing ligand receptor (TRAIL).
150
 The 
activation of the receptor (e.g. Fas) initiates a formation of the death-inducing 
signaling complex (DISC) at the cytosolic part of the receptor. The DISC-
complex, in this case, contains Fas-associated death domain protein (FADD) 
and caspases 8 and 10, which become activated. These may now activate the 
effector caspases 3, 6 and 7. Alternatively, caspase-8 may cleave inhibitor 
proteins of the intrinsic pathway, inducing activation of casapse-9. Caspase-9 
activates caspase-3, which further triggers caspase-8 activation, hence 
producing a positive feedback loop.
151
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The overall aim for this thesis is to determine the potential of the specific 
nephrotoxin, orellanine, as a curative treatment for advanced clear-cell renal 
cell carcinoma. 
It stems from the observation that orellanine apparently is toxic only towards 
the proximal tubular cells in the kidney, and is shown to accumulate in 
kidney cortex and is thought to accumulate in the proximal tubular cells. 
Therefore, we hypothesized that there is a selective and specific uptake 
mechanism of orellanine in these proximal tubular cells. Since clear cell renal 
cell carcinoma is thought to originate from the proximal tubular cells, we 
believed that also these cells would retain the same uptake mechanism for 
orellanine and hence also inherit the sensitivity for orellanine’s toxicity. 
 
To elucidate if orellanine is toxic for clear cell renal cell carcinoma (CCRCC) 
cells in vivo and in vitro. Further we wanted to study the cellular effects of 
orellanine. 
To establish a technique for the quantification of orellanine in solution and in 
plasma. 
To evaluate long-term effects in patients post orellanine intoxication. 
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All patients were diagnosed with orellanine poisoning and medical consent 
was given for each patient intoxicated during the period of 1979-2012. In 
total there were 28 patients who agreed to participate. They were admitted to 
hospitals in Borås, Gothenburg, Jönköping, Skövde, Trollhättan or Örebro. 
 
We reviewed the literature for a suitable model for CCRCC research. Since 
the animal will be dialysis dependent, the minimum size of the animal is 
confined; hence the mouse is too small for this purpose. The spontaneous RC 
model, the Eker rat,
152
 was found not to be suitable due to histological 
character of the tumors, not being CCRCC rather of a chromophobe 
subtype.
153
 In the Wistar-Lewis rat,
154
 adenocarcinoma arose spontaneously 
in a male rat and the tumor has been transplanted into syngeneic animals to 
keep it alive. The tumor develops into CCRCC carcinomas with metastatic 
potential to the lungs.
154,155
 Although this tumor shares several characteristics 
with human CCRCC, some features could still be lost or not transferable to 
hCCRCC. Therefore we decided to establish a human xenograft model of 
CCRCC in rat.  
The RNU-rat (strain NIH-Foxn1
rnu
, Charles River, Germany) was 
established at National Institute of Health in the 1979-1980 and came to 
Charles River in 2001.
156
 This rat is an athymic nude rat that lacks T-cells 
and is immune-deficient, making it suitable for xenograft research. We 
initially tried to establish a subcutaneous CCRCC model in these rats, to be 
able to follow the tumor growth easily in each individual.  
At first, hCCRCC were injected at the right flank of the animals. However, 
tumor growth in these rats ceased after 1-2 weeks, followed by a rapid 
reabsorption of the tumor. We attributed this effect to mobilization of the 
animals’ B-cell defense since the RNU-rat, while being T-cell deficient, has 
normal bone marrow-derived B-cell populations. In order to achieve 
continuous tumor growth for at least 5-6 weeks, which was required in order 
to study any antitumor effects of orellanine, we administered whole body 
irradiation in a dose range of 4-5 Gy. This suppressed B-cell mediated 
immune responses without apparent side-effects on appetite or general 
26 
behavior. Lower doses were inefficient, and significantly higher doses were 
lethal.  
 
Figure 4. Tumor volume and leukocyte concentration in irradiated RNU-rats 
 
Since orellanine is strongly toxic, not only to CCRCC but also to proximal 
tubular cells in the kidney, administration of orellanine will inevitably lead to 
kidney-failure, killing the animals within a few days. Therefore a dialysis 
system for rats was constructed to simultaneously replace the renal function 
of up to twelve animals for several weeks. 
In Sweden, one-third of all patients requiring dialysis receive peritoneal 
dialysis.
157
 The underlying principle is to use the abdominal cavity for 
dialysis fluid, the peritoneum as a dialyzer membrane, and glucose as the 
osmotic agent to remove excess of fluid. Briefly, the abdominal cavity is 
filled with a sterile PD-solution with physiological electrolyte composition, a 
buffer and hypertonic glucose content. The high glucose concentration will 
produce an osmotic driving force, causing water to leave the blood and enter 
the abdominal cavity. Waste products, like urea and creatinine, diffuse across 
the peritoneal membrane from the blood to the PD-solution due to the 
favorable concentration gradient. After the dwell-time, the solution in the 
abdominal cavity is drained and hence excess water and waste products are 
eliminated. The process is repeated several times per day to achieve adequate 
dialysis. 
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The general design of the system is illustrated in Figure 5. It operates 
completely without pumps, relying on hydrostatic pressure for filling as well 
as for draining the dialysate from the rats. It is a sealed system, which is kept 
sterile and autoclaved before each experiment and where the dialysis solution 
is warmed up before entering the rat. It is automated and computerized, and 
all fluid displacements are carried out by the opening and closing of valves. 
Fill times, dwell times and draining times can be set as desired in the 
customized software. It soon became apparent that the rat ideally requires 
constant dialysis during the majority of the day and night. This is likely due 
to its high metabolic activity and the correspondingly higher Kt/V number 
compared to humans. Although the system is fully automated, continuous 
monitoring is required, occasionally with rapid intervention, e.g. in the case 
of a valve failing to open or close properly. Typically we have performed 
dialysis over a period of 12-14 hours of the day for up to 2-3 weeks.   
 
Figure 5. Schematic illustration of the dialysis system for rats 
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1. The valve from the dialysis liquid reservoir is opened, 
allowing filling of the volume chamber with warm dialysis 
solution until the desired volume has been reached and the 
valve closes. 
 
2. The filling valve to the rat is opened, allowing the dialysis 
solution to pass from the volume chamber into the rat. 
 
3. Dialysis takes place for the set dwell time, usually 1 hour. 
 
4. The draining valve from the rat is opened and it is allowed to 
drain, typically for 30 minutes. 
 
5. The next cycle is initiated. 
 
 
It is extremely crucial to maintain an aseptic environment throughout the 
instrumentation procedure, since the animals are devoid of immunological 
capability and thus virtually defenseless against bacterial invasion.  
The day before the procedure, the rat is anesthetized using inhalation of 
isofluran  (2-4 % v/v Schering-Plough, Stockholm, Sweden) and thoroughly 
washed with DesCutan 4% (Fresenius Kabi AG, Bad Homburg, Germany), 
allowing the disinfectant to work for 5 minutes. The rat is rinsed with water, 
dried in sterile paper and placed in an autoclaved cage with autoclaved 
bedding and food.   
On the day of catheter insertion, anesthesia is induced and maintained using 
isofluran and the rat’s body is disinfected with chlorhexidine. Next, the rat is 
embedded in sterile coverings. A small incision is made in the neck and the 
animal is placed on its back on a heating plate covered with a sterile cloth. 
The rat is given Temgesic (0.3mg/kg, Schering-Plough, Stockholm, Sweden) 
for pain relief, and a bolus dose of 4 mg antibiotics (Ciprofloxacin) is 
administered sub-cutaneously. A 2 cm incision is made through the skin 
along the nodal line of the belly. Using a 20G needle, two holes, spaced 
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approximately 0.5 cm apart, are made along the white line of the peritoneum 
to allow access to the abdominal cavity without unnecessary bleeding or 
damage. A 1.5cm tip of a 5 Fr heparine-coated polyurethane catheter (Instech 
Laboratories, Inc., Plymouth Meeting, PA USA) is inserted into each hole 
and secured by suturing to the peritoneum. The catheters are tunneled sub-
cutaneously on the right hand side of the animal up to the neck and out via 
the incision and attached to a sterile dual luer harness (SAI infusion 
technologies, Libertyvill, IL, USA). Finally, the rat is placed in a new 
autoclaved cage and a swiveled metal tether-embedded tubing is attached to 
one of the harnesses’ valves via a luer connection. The animal is now ready 
for dialysis, but is left to recover for 48 hours before initiation of dialysis.  
 
Figure 6. Schematic overview of the in vivo studies in hCCRCC inoculated RNU- 
rats treated with orellanine. 
 
  
For detection of apoptosis in tumor sections, the ApopTag® Fluorescein In 
Situ Apoptosis Detection Kit (Millipore, Billerica, MA) was used. Formalin 
fixed and paraffin embedded tumor sections, 5μm thick, were de-paraffinized 
in xylene followed by an ethanol dilution series. For improved antigen 
retrieval, the sections were pressure boiled in a DIVA decloacker with DIVA 
solution (Biocare Medical, Concord, CA) for 30 minutes and dipped 10 times 
in Hot Rinse (Biocare Medical, Concord, CA). Sections were washed twice 
in PBS for 5 minutes at room temperature (RT) and then permeabilized with 
proteinase K (Millipore, Billerica, MA; 20 µg/ml in PBS) for 15 minutes at 
RT. After a 5 minutes wash in PBS, the sections were incubated in 
equilibration buffer at RT for 10 minutes. Next, the terminal deoxynucleotide 
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transferase (TdT) mixture was prepared and incubated for 1 hour at 37°C 
before the reaction was terminated by washing slides for 10 minutes in 
Stop/Wash buffer. Slides were then washed in PBS 3times for 1 minute 
before applying the Anti-Digoxigenin-conjugate and incubating for 1 hour at 
RT. Sections were finally washed 4 times for 2 minutes in PBS and mounted 
in ProLong Gold Antifade with DAPI nuclear staining (Life Technologies, 
Stockholm, Sweden). 
 
 
Human proximal tubular cells (HTEC) were prepared from a nephrectomy. 
An unaffected lobe was used and the cortex was cut out. In the cell culture, 
the cortex was minced carefully and transferred to a 15ml falcon tube. Next 
the minced tissue was washed three times with PBS and spun down in 
between at 500 rcf and the supernatant was taken off. After the last wash, the 
pieces were treated with sterile collagenase IV (1mg/ml medium) for 1 hour 
at 37°C. They were vortexed every 15 minutes for 10 seconds. The 
supernatant was then filtered through a 40μm cell strainer and spun down 5 
min at 500 rcf, the supernatant was taken off and cells were re-suspended in 
DMEM/Ham’s F12 medium with 10% FBS. This centrifugation re-
suspension step was repeated three times. Finally, the pellet was dissolved in 
DMEM/Ham’s F12 media supplemented with 10% FBS and 5ml PSA. The 
cells were seeded into two rat tail I collagen (5 ug/cm
2
, Becton Dickinson, 
Frankling Lakes, NJ) coated 25cm
2
 flasks. 
HTEC were seeded onto rat tail Collagen I coated cover slips and fixated in 
4% PFA in PBS for 15 minutes. They were stored in PBS in 4°C over-night. 
Next, the cells were blocked in 2%FBS and 2% BSA in distilled water for 1 
hour in room temperature (RT). Blocking solution was taken off and the 
primary antibody, neprilysin (Chemicon, Millipore, Billerica, MA) diluted 
1:100 in blocking buffer was applied to the cells and allowed to work for 1 
hour at RT. Cells were then washed with PBS for 70 minutes and then 
incubated with a secondary antibody, anti-rabbit Alexa 488 (Life 
Technologies, city, country), dissolved in blocking buffer, for 1 hour at room 
temperature. The slides are then washed with PBS for 1 hour at RT, rinsed 
with water and mounted with ProLong® antifade Gold with DAPI (Life 
Technologies, Stockholm, Sweden). About 90% of the cells were neprilysin 
positive. 
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The 786-O cells are a cell line available from the American Type Culture 
Collection (ATCC). It originates from a 58 year old male with clear cell renal 
cell carcinoma. It is a double mutant of the VHL-gene.
158
 The cells were 
cultured in DMEM High glucose, supplemented with 10% FBS and 5 ml 
PSA. The SKRC-cell lines (SKRC-7, -10, -17, -21 and -52) were all prepared 
and described by Ebert et al.
159
 SKRC-7, -10 and -21 are from primary 
tumors while SKRC-17 and -52 are from metastatic lesions, in soft tissue and 
mediastinum respectively. They were cultured in RPMI supplemented with 
10%FBS and 5 ml PSA or Antimycotic-antibiotic solution. All of them are 
clear cell renal cell carcinomas and they are either mutated or methylated in 
the VHL-gene, and hence do not express pVHL.
160
  The cells prepared from a 
primary CCRCC tumor (087) were from a female of age 48 years and were 
cultured as the SKRC-cells. 
 
The human umbilical vein endothelial cells (HUVEC) were purchased from 
Becton Dickinson (Becton Dickinson, Stockholm, Sweden) and cultured in 
EBM-2 media with bullet kit (Lonza, Basel, Switzerland). MDA-MB-231 
cells, from ATCC, are breast cancer epithelial cells derived from a metastatic 
lesion. They were cultured in DMEM high glucose, supplemented with 10% 
FBS and 5ml PSA. 
 
Alamar Blue (Life Technologies, Stockholm, Sweden) is a widely used assay 
to assess cytotoxic stress in cells. It has an advantage over the MTT assay in 
that the fluorescent compound is excreted by the cells, whilst in MTT the 
cells have to be lyzed to monitor the cytotoxicity. Especially during 
evaluation of toxicity with respect to time and/or dose, Alamar Blue has a 
great advantage over MTT, and was making it our choice when studying any 
toxic effects that orellanine exerts on various cell types. 
An initial Alamar Blue measurement was performed before exposing the 
cells to orellanine, controlling for any inequalities pre-treatment. Alamar 
Blue (1 ml) was mixed with 10 ml warm complete medium. 600 µl was then 
added to each well of a 12-well plate containing cells, and into 3 wells of an 
empty 12-well plate, serving as blanks. The plates were incubated for 2 hours 
at 37°C. Next, 200 µl of the alamar blue solution from each well was pipetted 
to a black 96-well plate. The fluorescence in the wells was monitored at 530-
560 nm excitation and 590 nm emission wavelengths, using a fluorescence 
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plate reader (Spectra Max Gemini XS, Molecular Devices, Sunnyvale, CA). 
The cells were washed twice with PBS and orellanine-containing medium 
was transferred to the wells at final orellanine concentrations of: 0, 4 20, 60, 
100 and 200 µg/ml. Cells were incubated for 24 hours at 37°C. Then 
orellanine containing medium was removed, cells were washed twice with 
PBS and then restored in 37°C. The Alamar blue measurement was done at 
48, 72, 96 and 144 hours respectively post orellanine treatment. 
 
 
Western blotting was used for monitoring of differences in caspase cleavage 
in vehicle or orellanine treated SKRC-52 cells. The cells were lysed on ice 
using a cell scraper and a lysis buffer containing: 150 mM NaCl, 100 mM 
Tris HCl, 2 mM EDTA, dH2O and 100 mM TritonX-100. Equal 
concentration of whole cell protein lysates were separated on NuPAGE Bis-
Tris gels 4-12% (Novex, San Diego, CA). They were transferred to 
polyvinylidene difluoride (PVDF) membranes and blocked in 5% nonfat dry 
milk (BioRad) in tris buffered saline with Tween 20 (TBS-T) at room 
temperature for 1 hour and incubated with primary antibody (1:500) (Cell 
Signaling Technology, Inc., Danvers, MA), in 5% milk in TBS-T at 4°C 
over-night. The membrane was washed 4*15 minutes in TBS-T and was then 
incubated with secondary antibody (1:1000) at room temperature for 1 hour 
followed by an hour washing in TBS-T. Incubation with Immun-Star 
WesternC kit and CCD-camera (Molecular Imager Chemidoc XRS+ 
Systems, Bio-Rad Laboratories Inc., Hercules, CA) was used to visualize 
immunoreactive bands. 
 
Caspase activity assay kits (Abcam, Ltd, United Kingdom), were used to 
detect apoptosis induction in orellanine treated SKRC-17 and SKRC-52 cells. 
The caspases investigated were caspase 3, 8 and 9. 
SKRC-17 and SKRC-52 cells were lysed on ice using a cell scraper and a 
lysis buffer containing: 150 mM NaCl, 100 mM Tris HCl, 2 mM EDTA, 
dH2O and 100 mM TritonX-100. The lysates were aliquoted and were frozen 
immediately in -20°C except for one aliquote from each sample, which was 
used for protein measurement according to manufacturer’s protocol (Pierce 
BCA Protein assay kit, Pierce Biotechnology, Rockford, IL). At the day for 
activity measurement, samples were thawed and diluted with dH2O to yield 
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an equal protein concentration of each sample. 50 μl of equal amount of 
protein were pipetted into a 96-wells plate. Next, 50 ul Reaction buffer 
containing DTT, according to manufacturer’s protocol, were pipetted into all 
the samples of the 96-well plate. Finally, 5 μl of the substrate for each 
caspase was added to the wells, the plate was shaken lightly and was then 
incubated at 37°C for 2 hours in the dark. The fluorescence of the cleaved 
substrates and hence the caspase activity, was determined at an excitation 
wavelength of 400 nm and an emission wave length of 505 nm on a 
fluorescence plate reader (Spectra Max Gemini XS, Molecular Devices, 
Sunnyvale, CA).  
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This thesis is based on three papers. The aim of paper I was to elucidate the 
effects of orellanine on clear cell renal cell carcinoma in vitro and further 
study its effect in vivo in a model of human CCRCC in rat. In paper II, an 
LC-MS model was outlined for the detection of orellanine in solution (e.g. 
plasma). In paper III, the long term effects of orellanine in patients were 
investigated in a case-controlled study. 
 
Orellanine induces kidney failure by shutting down the proximal tubular cells 
in the kidney. In paper I, we confirm the toxicity of orellanine towards human 
proximal tubular cells (HTEC) in terms of reduced viability over time (Figure 
7). The sensitivity of these cells to orellanine is evident also for the lowest 
dose tested (4μg/ml). In contrast, CCRCC cells are only slightly affected 
when treated with 4μg/ml for 144 hours (Figure 8). Interestingly, the two cell 
lines from metastatic lesions (SKRC-17 and -52) require higher doses to be 
affected as is evident at the concentration of 20μg/ml. The 087 cells, prepared 
fresh from a primary tumor, and the primary CCRCC cell lines (786-O and 
SKRC-10) are more sensitive to orellanine. SKRC-52 has been histologically 
identified as having a high sarcomatoid component
107
 and the SKRC-17 
tumors from our animal studies, were shown to be poorly differentiated 
(anaplastic). Both of these characteristics are associated with a worsened 
prognosis and also treatment resistance. Note however, that all renal cancer 
cells tested show low viability at doses of orellanine of 60μg/ml and higher. 
 
 
 
 
 
Figure 7. Reduction in viability in HTEC after 24 hours treatment with orellanine at 
the indicated doses and the time-points specified.  
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The control cell lines, human umbilical vein endothelial cells (HUVEC) and 
MDA-MB-231 (noted MDA), cells from a metastatic breast cancer, were 
both unaffected by orellanine except at the highest concentrations. This 
suggests that there is a therapeutic window where orellanine effectively kills 
all clear cell renal cancer cells while leaving other cells substantially 
unaffected. 
 
Figure 8. Viability 144 hours post 24 hours orellanine treatment at the indicated 
doses. 
 
 
Orellanine seems to be taken up by the proximal tubular cells in the 
kidney.
134
 To address the nature of orellanine uptake into HTEC and 
CCRCC, cells were cooled down to 8°C to stop all active transport,
161,162
 
allowing only diffusion to take place. Cells treated with orellanine at 37°C 
had a reduced viability, while the cells incubated with the toxin at 8°C were 
protected completely. The same pattern was observed in all of the three cell 
lines investigated (HTEC, SKRC-17 and SKRC-52). This demonstrates that 
the uptake mechanism for orellanine is an active process. Most importantly, 
the active transport mechanism is present also in the poorly differentiated 
renal cancer metastases, such as SKRC-17 and SKRC-52 cells. 
 
The exact mechanism for the transportation of orellanine into proximal 
tubular cells is still unknown. We hypothesize that there is a specific 
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transporter that transports orellanine into the proximal tubular cell, either 
from the apical side or from the interstitial side. Orellanine is present mainly 
as a diglucoside, both in the fruit body of the fungus and when analyzed in 
plasma samples (Paper II). A hypothesis raised by Rohrmooser et al, is that 
orellanine is taken up as a glucoside into the proximal cell.
134
  Once within 
the cell, the glucose groups are cleaved off, and orellanine, which is unable to 
diffuse across the cell membrane, would then rapidly accumulate into toxic 
concentrations. Orellanine may also be bound to, for example, a protein and 
co-transported into the cells. 
Our initial candidate transporter was SGLT-2, found abundantly, but not 
exclusively, on the apical membrane of proximal tubular cells in the 
kidneys
163
 Phlorizin, a non-selective inhibitor of SGLT-2,
164
 resembles 
orellanine structurally. Therefore, we speculated that while phlorizin binds to 
and inhibits SGLT-2, orellanine is actually transported into the cells by the 
same transporter. However, a specific SGLT-2 blocker did not protect the 
cells from the toxicity of orellanine, indicating that SGLT-2 is not the 
orellanine transporter that we are looking for. 
To further analyze the properties of orellanine transport into proximal 
epithelium, sodium-dependence was studied. Indeed, most substances 
reabsorbed from the urine enter the proximal tubular cells by one of several 
sodium-co-transporters. Therefore, we wanted to study if orellanine could be 
prevented from entering the cell and hence exert its toxicity by reducing the 
extracellular sodium concentration from145mM to sub-cellular concentration 
of sodium (7mM),
165
 with choline added instead of sodium to maintain 
identical osmolality. However, the toxicity of orellanine-treated cells 
incubated at low or normal sodium concentration was similar. This strongly 
indicates a sodium-independent transport of orellanine.  
Next, we sought to identify sodium-independent transporter candidates 
present on proximal tubular cells. Some of these are mentioned in the 
introduction, like OAT1, 3 and 4, OCT 1 and 2, and MATE1. This is still 
ongoing work. 
 
Since we observed a pronounced decrease in viability of renal cancer cells 
treated with orellanine, our aim was to investigate whether this was due to 
induction of apoptosis. Indeed, we could detect an activation of caspase-3, an 
executor of apoptosis, in SKRC-52 cells when exposed to orellanine. Next 
we sought to identify which of the apoptotic pathways that were activated; 
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the intrinsic or the extrinsic pathway. To do this, we studied caspase-9 and 
caspase-8 activation, respectively. With western blotting, only caspase-8 
activation was detected (Figure 9a). To further confirm caspase activation, 
we used caspase activity kits. Results showed an activation of caspase-3 and 
caspase-9 in SKRC-52 cells (Figure 9 b,d). A tendency towards caspase-8 
activation was observed, but this was not statistically significant (p=0.09) 
(Figure 9c). This shows that the caspase activity measurement might be a 
more sensitive analysis than Western blotting in terms of caspase activation. 
The caspase-9 levels of activity were very low, which may explain why it 
was difficult to identify the activation by western blotting. In SKRC-17 cells, 
all the three caspases were significantly activated. Thus, orellanine induces 
apoptosis in the two CCRCC cell lines, probably via both the intrinsic and 
extrinsic pathways.  
Figure 9. Caspase activation in SKRC-52 cells after treatment with orellanine, 100 
μg/ml for 2, 6 or 24 hours. 
 
We have shown that orellanine reduces the oxidative stress defense in HTEC 
and induce ROS in both HTEC and the CCRCC cell line SKRC-52. This is 
consistent with previous observations in vivo, where increased ROS-levels 
were observed in tubular cells in kidney sections of orellanine treated rats.
166
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Also a decrease in mRNA-level for several antioxidant enzymes was detected 
in kidney cortex from the same animals. The exact mechanisms behind the 
observed effects remain unclear. However, it is a highly interesting 
phenomenon that oxidative stress is observed in concert with decreased 
oxidative stress defense, which may be one explanation of orellanine’s 
toxicity. However, further investigation in terms of molecular steps and 
pathways is required for this to be fully elucidated.  
 
To further investigate if the results in vitro were reproducible in vivo, and 
could be used in the clinical setting, a tumor model of human CCRCC in rat 
was developed, as described in section 3.2. Furthermore, a peritoneal dialysis 
system for rats was constructed (see section 3.3). 
 
For the tumor model, a cell line from a metastatic CCRCC lesion (SKRC-17) 
was used to mimic a metastatic model of human CCRCC. 
In animals, treated with 10mg/l orellanine, for 2 days, 9 days after tumor cell 
implantation, the tumor weight was significantly smaller in treated rats 
compared to control animals (1.0g versus 4.5 g). The control rats did not 
receive dialysis and tumors were assessed after a mean of 9 days post-
treatment initiation. Necrosis in the remaining tumor was also increased in 
the treated animals (65%) compared to control (15%). In another setting, 
animals were treated early on, 4 days after inoculation, with the same 
(10mg/l) or a higher dose of orellanine (20mg/l), with treatment for 5 days or 
3 days, respectively. In this study, the control rats received one cycle of 
dialysis per day. The effect on tumor weight was even more pronounced 
(control 0.98g, 10mg/l: 0,11g and 20mg/l: 0.07g) with p< 0.001 for both 
treatment groups, assessed 5 days post treatment initiation. In tumors from 
animals treated with 20mg/l, necrosis was significantly increased. Apoptosis 
was increased in both treatment groups compared to control (p< 0.01 10mg/l 
and 0.001 20mg/l) (Figure 10). Taken together, a more pronounced effect 
was seen on tumor volume, apoptosis and necrosis when treating animals 
with higher doses of orellanine for a shorter time period.  
Although we have chosen to use the more anaplastic, fast-growing SKRC-17 
cells in our tumor model, we still observe pronounced effects on tumor 
volume, induction of apoptosis and necrosis. As discussed earlier in section 
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4.1, the SKRC-17 was one of the CCRCC cell lines with the lowest 
sensitivity for orellanine. This supports the hypothesis that orellanine has a 
significant effect in the clinical setting, where generally, the metastatic 
lesions resemble the primary tumors histologically. Even if this was not the 
case, our data implies that even highly resistant tumors, with a sarcomatoid 
component or with anaplastic appearance, are likely to respond to the 
treatment. 
 
 
 
 
 
 
Figure 10. Apoptosis in tumor sections from RNU-rats treated with orellanine. 
 
 
In order to be able to measure the orellanine distribution and uptake we 
wanted to establish a new and highly sensitive method. Methanol (MeOH) 
has been previously used as an extraction solvent for orellanine.
133,167,168
 Here 
we investigated four different extraction solvents for orellanine: MeOH, 
MeOH/3M HCl (10:1), water and 3M HCl. Of these, 3M HCl was the 
superior extraction solvent, followed by water, acidified MeOH and MeOH. 
An interesting finding was that in both water and 3M HCl, any glucosides of 
orellanine were rapidly hydrolyzed to orellanine. In acidified MeOH, this 
hydrolyzation took place, consistent with previous data,
167
 but to a smaller 
and slower extent while in the MeOH, no hydrolyzation was identified and 
hence less free orellanine was detected. It was also observed that the majority 
of orellanine in the mushroom extract initially appeared to be in the 
diglucoside and monoglucoside forms, as has been suggested previously.
167
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In patients suffering from accidental orellanine poisoning, the toxin is not 
detectable in urine or plasma after onset of symptoms, and orellanine is only 
to be found in kidney biopsies at that time. However, in a clinical setting 
using orellanine as a treatment of patients with mCCRCC, a careful 
monitoring of the serum concentration of orellanine will be crucial to provide 
a satisfactory treatment paradigm. For this purpose, a technique using high-
performance liquid chromatography combined with electrospray ionization 
tandem mass spectrometry (HPLC-ESIMS/MS) for quantitative 
measurements was established. This method has previously been used only 
for qualitative detection of the diglucoside of orellanine
167
 and was now 
optimized. The technique displayed high sensitivity and could detect 
orellanine concentrations down to 5ng/ml or less. In the treatment of animals 
with CCRCC (Paper I), the orellanine concentration most frequently used 
was 10mg/l (10μg/ml), which would be the maximum theoretical plasma 
concentration in these animals. This is 2000 times higher than the limit of 
detection with the method established, hence the technique will be suitable 
for detection of serum concentrations of orellanine within the treatment 
range. 
 
 
 
 
 
 
 
 
Figure 11. Chemical structures of monoglucoside of orellanine at the top and 
diglucoside of orellanine at the bottom. 
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Orellanine is known to induce renal failure after ingestion of Cortinarius 
mushrooms. Depending on the amount of mushroom and hence orellanine 
ingested, the outcome for the patient differs. Some patients never require 
dialysis and will recover most of their renal function, while others will need 
dialysis for a transient period, or for life. Acute symptoms due to orellanine 
intoxication have been well studied. 
128,130,169-171
 We wanted to investigate 
whether orellanine-induced end-stage kidney failure (CKD5), leading to life-
long dialysis dependence or transplantation, would lead to increased 
mortality or other non-kidney related effects/morbidity, mortality or higher 
cancer frequency. Furthermore, additional clinical parameters were also 
investigated in the Cortinarius-group. We included all patients agreeing to 
participate in the study with a clinical diagnosis of mushroom poisoning from 
6 hospitals. 
In the Cortinarius-group of patients, other than renal failure, liver function in 
terms of enzymatic activity and blood values were examined. All values were 
in the normal range, and hence no abnormalities were observed. As expected, 
both urea and creatinine serum levels were higher in patients being dialysis-
dependent after intoxication compared to patients whose remaining kidney 
function was sufficient, and hence not needing any dialysis (Figure 12). 
 
 
 
 
 
Figure 12. Peak creatinine and serum levels in patients needing dialysis or not, post 
intoxication with orellanine containing mushrooms.  
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Next, patients with CDK5 were age and sex matched with control patients 
that were transplanted or initiated on dialysis the same year, in a randomized 
and blinded manner. Of the 21 patients in the orellanine group, 20 were 
matched, 7 on dialysis and 13 of the 14 transplanted patients. Results showed 
5 deaths in the Cortinarius-group and 6 in the case control population and 
hence there was no statistical significance in deaths between the two 
populations. Similarly, in terms of cancer, 4 patients in each group were 
diagnosed with cancer. However, cancer was the cause of death only in one 
patient in the entire population, belonging to the case control group.  
Hence the patients in the Cortinarius and the case control group do not 
significantly differ between the groups. This indicates that orellanine 
intoxication per se, is not a cause for increased mortality or higher cancer 
frequency. Furthermore, we could not detect any other clinical symptoms, 
except for renal failure, in orellanine-intoxicated patients. These are 
important findings in terms of using orellanine as a treatment for mCCRCC. 
 
In the pathophysiological setting of mushroom intoxication, orellanine is 
taken up by cells in the intestine, circulated in blood, eliminated by 
glomerular filtration and/or tubular secretion, and is probably accumulated in 
the proximal tubular cells in the kidneys. The toxin can no longer be detected 
in body fluids after 3-6 days, when the patient experiences their uremic 
symptoms.
134
 As seen in Paper I, control cells exposed to orellanine in vitro 
are insensitive to orellanine at the concentrations used in the in vivo settings 
for killing renal cancer cells (20μg/ml). Furthermore, in Paper III, liver 
values were normal and no side-effects, other than kidney failure, were 
reported. Additionally, no increased mortality was observed due to acute 
orellanine toxicity. During treatment of a patient with metastatic CCRCC, 
orellanine will not only be taken up by the kidneys but also by the metastatic 
lesion, and its toxicity will hypothetically eliminate the tumor. This is what 
we observed in our rat model of CCRCC. The serum concentration of 
orellanine will be carefully monitored with the improved technique that we 
developed in Paper II, to be able to optimize the treatment regime. In all, by 
these investigations we have taken the first crucial steps towards an 
essentially new therapy for metastatic clear cell renal carcinoma with a true 
curable potential. However, important questions remain unanswered, 
especially in terms of how orellanine is taken up by the cells and its 
intracellular mechanisms. Furthermore, animal toxicity studies also need to 
be performed before orellanine can be tested in the clinical setting.  
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Figure 13. Schematic illustration of the signaling pathways induced by orellanine in 
HTEC and/or CCRCC. The gray arrows indicate previously described findings in 
renal cortex. OR=orellanine, ROS=reactive oxygen species, ATP=adenosine 
triphosphate. 
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The major findings in this thesis are: 
1. The nephrotoxin, orellanine, is highly toxic to human 
CCRCC cells while other cell types are unaffected at 
therapeutic concentrations. 
 
2. In a proof of concept study in rodents, human CCRCC are 
effectively destroyed and the animals appear unharmed and 
survive on dialysis.  
 
3. Orellanine can be quantitatively detected down to 5ng/ml 
with our optimized HPLC-ESIMS/MS system. This 
technique is stable and sensitive and will give excellent 
measurements of serum concentrations in patients treated 
with orellanine in the clinical setting. 
 
4. Patients suffering from orellanine intoxication do not differ 
from the case-control group in terms of survival or cancer 
incidence. Liver status and blood values were normal, thus 
renal failure remains the solely known outcome of orellanine 
intoxication. 
 
Taken together, our results show that orellanine does affect aggressive human 
CCRCC both in vitro and in vivo and does not have any other effects apart 
from renal failure, which can be well managed with dialysis or kidney 
transplantation. Patients with metastatic CCRCC lack curative treatment to 
date and have a bad prognosis with a 5-year survival of less than 10%. We 
conclude that orellanine has potential to become a novel curative treatment 
for these patients and that further research into the matter is highly motivated. 
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We have shown orellanine’s potential as a curative treatment of mCCRCC. 
There are several interesting and challenging areas that should be further 
explored. 
 
We have observed reduced levels of anti-oxidative enzymes in concert with 
increased oxidative stress in proximal tubular cells treated with orellanine. 
Increased ROS was also detected in SKRC-52 cells after orellanine treatment. 
Additionally, apoptosis was detected due to orellanine treatment in the two 
cancer cell lines studied (SKRC-17 and SKRC-52). This led us to 
hypothesize that orellanine treatment, which reduces the ROS-defense and 
concomitantly increases ROS, in this way triggers apoptosis of the cells. It 
would be interesting to study if ROS indeed is the trigger of the apoptosis 
observed. To address this, different ROS-scavengers (e.g. Tempol® and 
NAC) could be used, to see if the cells can be rescued from apoptosis with 
this treatment. It would also be interesting to investigate whether the ROS 
induced is especially severe on different compartments of the cell, like the 
mitochondrion. The mitochondrion specific ROS-scavenger, mito-Tempol, 
could be used to examine this. 
 
To further prove that orellanine is selectively and actively taken up by HTEC 
cells and CCRCC cells, we have made tritium-labeled orellanine, which can 
be used for this purpose. After orellanine treatment, cells are washed 
carefully and run in a radiometer for the detection of radioactivity. This 
should also be applied on control cells (e.g. HUVEC), in which we 
hypothesize that no radioactivity will be detected. To further prove 
orellanine’s cellular localization within the kidney, rats may be injected with 
the radiolabeled orellanine and kidney tissue sections can be examined for 
radioactivity. 
As mentioned in the results and discussion section, we are currently 
searching for the transporter(s) of orellanine. This is important for several 
reasons, i.e. to understand the molecular transportation and uptake-
mechanism. If we find the transporter, the metastatic lesion or mother tumor 
46 
might be biopsied and screened for the receptor, so only patients that will 
respond to treatment will undergo orellanine therapy. Finding the transporter 
could further help to potentiate orellanine, in terms of using targeted radiation 
therapy connected to orellanine, directing it specifically to the cancer cell. 
 
Orellanine has been shown to be toxic to both proximal tubular cells as well 
as CCRCC cells, which are thought to evolve from the former cell type. The 
second most common RCC, papillary renal carcinoma, is considered to 
originate from distal tubular cells.
172
 However, in a study published 2010, the 
similarity of papillary RCC and the stem cell of proximal tubular cells was 
indicated.
173
 Perhaps this cancer cell type, if evolved from a proximal tubule 
stem cell, still might have the transporter for orellanine present on its cell 
surface and hence share the sensitivity for orellanine? It would of course be 
very interesting to investigate if orellanine could be used as a treatment for 
the two most common forms of RCC. 
 
Results from our studies have further encouraged the evolvement of 
orellanine into a treatment of mCCRCC. Toxicity studies in rats will be 
performed during summer 2014. Presently, orellanine toxicity is evaluated in 
vitro on several primary CCRCC, CCRCC cell lines as well as a range of 
control cells, like human glomerular endothelial cells and mesangial cells. If 
these results are promising, this is of course our main goal, to transfer our 
findings into the clinical setting and hopefully offer a new and curative 
treatment for these patients.  
 
Figure 14. Schematic summary over future perspectives. OR=orellanine 
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The TNM-staging gives a guideline for both treatment and patient outcome. 
For renal cell carcinoma, the system was revised in 2010 and the guidelines 
are as follows:  
        
                          Primary tumor (T)   
  
TX Primary tumor cannot be assessed 
  
  
T0 No evidence of primary tumor 
  
  
T1 Tumor ≤7 cm in greatest dimension, limited to the 
kidney   
  
 T1a Tumor ≤4 cm in greatest dimension, limited to 
the kidney   
  
 T1b Tumor >4 cm but not >7 in greatest dimension,                                      
limited to the kidney 
  
  
T2 Tumor >7cm in greatest dimension, limited to the 
kidney   
  
 T2a Tumor>7 cm but ≤10 cm in greatest dimension,                                               
limited to the kidney 
  
  
 T2b Tumor >10 cm, limited to the kidney 
  
  
T3 Tumor extends into major veins or perinephric 
tissues not beyond Gerota fascia 
  
  
 T3a Tumor extends into major vein or its segmental 
branches or invades perirenal and/or renal sinus fat 
but not beyond Gerota fascia   
  
 T3b Tumor grossly extends into vena cava below 
diaphragm   
  
 T3c Tumor grossly extends into vena cava above the 
diaphragm or invades the wall of vena cava   
  
T4 Tumor invades beyond Gerota fascia 
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  Regional Lymph Nodes (N)   
  
NX Regional lymph nodes cannot be assessed 
  
  
N0 No regional lymph node metastasis 
  
  
N1 Metastases in regional lymph node(s) 
  
        
        
         Distant Metastasis (M)   
  
M0 No distant metastasis 
  
  
M1 Distant metastasis 
  
        
 
            
        Stage Grouping     
  
  
  
  
  Stage I T1 N0 M0   
  Stage II T2 N0 M0   
  Stage III T3 N0 M0   
  
 
T1-T3 N1 M0   
  Stage IV T4 Any N M0   
  
 
Any T Any N M1   
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